Heineken has warned British bars and pubs that the boom in popularity of weight-loss drugs could lead to a fall in sales of beer and cider.
The world’s second-largest brewer sent a presentation to British hospitality customers earlier this month that said the use of GLP-1 medication – such as Ozempic and Wegovy – could reduce the desire to drink alcohol. This in turn could result in “fullness and fewer serves” of pints in pubs and bars, it added.
